Are PROMIS and Legacy Patient-Reported Outcome Measures Correlated for Patients Undergoing Carpal Tunnel Release?

对于接受腕管松解术的患者,PROMIS 和传统患者报告结局指标之间是否存在相关性?

阅读:1

Abstract

PURPOSE: Long-established patient-reported outcome measures (PROMs), such as the Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) and the QuickDASH, have been used traditionally to measure baseline symptoms and treatment effects before and after carpal tunnel release (CTR), but more recently, the Patient-Reported Outcomes Measurement Information System (PROMIS) has been used increasingly in the CTR patient population. We aimed to measure the correlation between legacy and PROMIS PROMs for baseline pain and function in a cohort of patients undergoing CTR for idiopathic carpal tunnel syndrome (CTS). METHODS: Baseline PROMs were collected prospectively in 86 patients with electrodiagnostically confirmed CTS treated with CTR at a single tertiary referral center. The legacy PROMs used were the BCTQ and the QuickDASH. The PROMIS instruments used were computer adaptive test versions of the PROMIS Pain Interference (PI), Upper Extremity (UE), and Physical Function (PF). Given normal distributions, correlation between PROMs was assessed using the Pearson correlation coefficient. RESULTS: The mean age of the cohort was 59.7 years, and 56% were women. When assessing pain, the BCTQ - Symptom Severity Scale (SSS) was correlated moderately with PROMIS - PI (ρ = 0.59). When assessing function, the BCTQ - Functional Status Scale (FSS) was strongly inversely correlated with PROMIS - UE (ρ = -0.71) and moderately inversely correlated with PROMIS - PF (ρ = -0.58). The QuickDASH was strongly inversely correlated with PROMIS - UE (ρ = -0.75) and moderately inversely correlated with PROMIS - PF (ρ = -0.62). Finally, when comparing the two legacy PROMs for function, the BCTQ - FSS was strongly correlated with QuickDASH (ρ = 0.88). CONCLUSIONS: We demonstrated at least moderate correlation between legacy and PROMIS outcome measures of baseline pain and function in CTS patients. CLINICAL RELEVANCE: Our findings support the use of either legacy or PROMIS outcome measures for this patient population.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。